FWIW, I had bought into LXRX last year on a low and sold 60% of my shares yesterday on the run-up on their announcement of LX4211. This was good news..........just not ground breaking as this was known from previous trials. They have a few other compounds in studies which should give top line data this year so I am holding my 40% almost free shares for that and for partnership announcement.
HIMX (from $1.90 and $2.80), LXRX, GTAT and MU. What a year it has been..........thus far.